• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Definitive radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004)].

作者信息

Beier Josephine, Rühle Alexander

机构信息

Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Leipzig, Stephanstraße 9a, 04103, Leipzig, Deutschland.

Partnerstandort Leipzig, Mitteldeutsches Krebszentrum (CCCG), Leipzig, Deutschland.

出版信息

Strahlenther Onkol. 2025 Apr;201(4):475-477. doi: 10.1007/s00066-025-02370-7. Epub 2025 Feb 4.

DOI:10.1007/s00066-025-02370-7
PMID:39904780
Abstract
摘要

相似文献

1
[Definitive radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004)].[西妥昔单抗或度伐鲁单抗用于顺铂禁忌的局部晚期头颈癌患者的根治性放疗（NRG-HN004）]
Strahlenther Onkol. 2025 Apr;201(4):475-477. doi: 10.1007/s00066-025-02370-7. Epub 2025 Feb 4.
2
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.西妥昔单抗或度伐利尤单抗用于顺铂禁忌的局部晚期头颈癌患者的放疗（NRG-HN004）：一项开放标签、多中心、平行组、随机、2/3期试验。
Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14.
3
Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.评估接受顺铂或西妥昔单抗或不放疗治疗局部晚期头颈部癌老年患者的照护价值。
JAMA Otolaryngol Head Neck Surg. 2019 Dec 1;145(12):1160-1167. doi: 10.1001/jamaoto.2019.2381.
4
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer.NRG/RTOG 0522 的长期更新：局部晚期头颈部癌同步放化疗加或不加西妥昔单抗的随机 3 期临床试验。
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):533-543. doi: 10.1016/j.ijrobp.2022.12.015. Epub 2022 Dec 19.
5
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.美国接受西妥昔单抗或顺铂治疗局部晚期头颈部鳞状细胞癌患者的生活质量分析。
Health Qual Life Outcomes. 2020 Jun 22;18(1):195. doi: 10.1186/s12955-020-01424-x.
6
Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.根治性放疗联合顺铂或西妥昔单抗治疗头颈部癌患者的生存：监测、流行病学和最终结果-医疗保险分析。
Cancer. 2018 Dec 1;124(23):4486-4494. doi: 10.1002/cncr.31708. Epub 2018 Oct 17.
7
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.ARTSCAN III 研究：比较局部晚期头颈部鳞状细胞癌患者接受顺铂同期放化疗与西妥昔单抗治疗的随机 III 期研究
J Clin Oncol. 2021 Jan 1;39(1):38-47. doi: 10.1200/JCO.20.02072. Epub 2020 Oct 14.
8
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.术后顺铂化疗联合放疗优于西妥昔单抗联合放疗和单纯放疗：奥地利头颈部癌症登记处的 AGMT 分析。
Wien Klin Wochenschr. 2021 Nov;133(21-22):1131-1136. doi: 10.1007/s00508-021-01939-3. Epub 2021 Sep 15.
9
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.紫杉醇联合西妥昔单抗用于不适合铂类化疗的局部晚期头颈部鳞状细胞癌患者的诱导化疗
Front Oncol. 2022 Jul 22;12:953020. doi: 10.3389/fonc.2022.953020. eCollection 2022.
10
A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck.一项比较西妥昔单抗和顺铂对局部晚期头颈癌患者进行调强放疗同步放化疗时急性毒性的研究。
Cureus. 2021 Jul 20;13(7):e16505. doi: 10.7759/cureus.16505. eCollection 2021 Jul.

本文引用的文献

1
[Pembrolizumab in combination with radiochemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: results of the KEYNOTE-412 study and the challenges of radioimmunotherapy].帕博利珠单抗联合放化疗治疗局部晚期头颈部鳞状细胞癌：KEYNOTE-412研究结果及放射免疫治疗的挑战
Strahlenther Onkol. 2024 Dec;200(12):1097-1099. doi: 10.1007/s00066-024-02315-6. Epub 2024 Oct 16.
2
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.帕博利珠单抗联合同步放化疗对比安慰剂联合同步放化疗用于局部晚期头颈部鳞状细胞癌患者（KEYNOTE-412）：一项随机、双盲、3期试验
Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29.
3
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.同期卡铂和紫杉醇根治性放疗局部晚期头颈部癌症。
Head Neck. 2023 Sep;45(9):2207-2216. doi: 10.1002/hed.27456. Epub 2023 Jul 13.
4
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.头颈部癌症患者中多西他赛作为放射增敏剂的 III 期随机试验结果，不适合顺铂为基础的放化疗。
J Clin Oncol. 2023 May 1;41(13):2350-2361. doi: 10.1200/JCO.22.00980. Epub 2023 Jan 27.
5
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.帕博利珠单抗与西妥昔单抗联合放疗用于不适合顺铂治疗的局部晚期头颈部鳞状细胞癌患者（GORTEC 2015 - 01 PembroRad）：一项多中心、随机、II期试验
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
6
Patterns-of-Care Analysis for Radiotherapy of Elderly Head-and-Neck Cancer Patients: A Trinational Survey in Germany, Austria and Switzerland.老年头颈癌患者放射治疗的护理模式分析：德国、奥地利和瑞士的三国调查。
Front Oncol. 2022 Jan 3;11:723716. doi: 10.3389/fonc.2021.723716. eCollection 2021.
7
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.avelumab 联合标准治疗放化疗对比单纯放化疗用于局部晚期头颈部鳞状细胞癌患者：一项随机、双盲、安慰剂对照、多中心、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3.
8
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.放疗联合西妥昔单抗或顺铂治疗人乳头瘤病毒阳性口咽癌（NRG 肿瘤学 RTOG 1016）：一项随机、多中心、非劣效性试验。
Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.
9
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.放疗联合顺铂或西妥昔单抗治疗低危型人乳头瘤病毒阳性口咽癌（De-ESCALaTE HPV）：一项开放标签随机对照 3 期临床试验。
Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.
10
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.放疗联合西妥昔单抗治疗头颈部鳞状细胞癌。
N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.